Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-small Cell Lung Cancer (NSCLC) · EGFR Mutation-Positive Lung Cancer · Brain Metastases · Leptomeningeal Metastases · Intracranial Tumor Progression
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China